Wave Life Sciences (0VS) Stock Overview
A clinical-stage biotechnology company, focuses on unlocking the ribonucleic acid (RNA) medicines to transform human health. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
0VS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Wave Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.06 |
| 52 Week High | US$17.80 |
| 52 Week Low | US$4.60 |
| Beta | -1.29 |
| 1 Month Change | -2.71% |
| 3 Month Change | -8.85% |
| 1 Year Change | -24.49% |
| 3 Year Change | 21.03% |
| 5 Year Change | 3.82% |
| Change since IPO | -85.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0VS | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 7.6% | -1.9% | 0.5% |
| 1Y | -24.5% | 46.3% | 4.4% |
Return vs Industry: 0VS underperformed the German Pharmaceuticals industry which returned 51.8% over the past year.
Return vs Market: 0VS underperformed the German Market which returned 3.7% over the past year.
Price Volatility
| 0VS volatility | |
|---|---|
| 0VS Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 0VS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0VS's weekly volatility has decreased from 23% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 317 | Paul B. Bolno | wavelifesciences.com |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, focuses on unlocking the ribonucleic acid (RNA) medicines to transform human health. Its PRISM platform combines various modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers) provides with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Wave Life Sciences Ltd. Fundamentals Summary
| 0VS fundamental statistics | |
|---|---|
| Market cap | €1.04b |
| Earnings (TTM) | -€175.42m |
| Revenue (TTM) | €56.64m |
Is 0VS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0VS income statement (TTM) | |
|---|---|
| Revenue | US$65.37m |
| Cost of Revenue | US$197.42m |
| Gross Profit | -US$132.05m |
| Other Expenses | US$70.42m |
| Earnings | -US$202.47m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.03 |
| Gross Margin | -202.00% |
| Net Profit Margin | -309.73% |
| Debt/Equity Ratio | 0% |
How did 0VS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/11 13:38 |
| End of Day Share Price | 2026/08/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wave Life Sciences Ltd. is covered by 28 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Whitney Ijem | Canaccord Genuity |